David Robert Sibley

David Robert Sibley's AcademicInfluence.com Rankings

David Robert Sibley

Biology

#7353

World Rank

#10262

Historical Rank

Neuroscience

#943

World Rank

#982

Historical Rank

biology Degrees

Download Badge

Biology

David Robert Sibley's Degrees

Bachelors Biology University of California, Berkeley
PhD Neuroscience Stanford University

Similar Degrees You Can Earn

Best Online Bachelor's in Biology 2026

Why Is David Robert Sibley Influential?

(Suggest an Edit or Addition)

(See a Problem?)

David Robert Sibley's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. (1990) (2909)
Molecular biology of dopamine receptors. (1992) (1062)
Aripiprazole, A Novel Atypical Antipsychotic Drug with a Unique and Robust Pharmacology (2003) (867)
Molecular mechanisms of receptor desensitization using the β-adrenergic receptor-coupled adenylate cyclase system as a model (1985) (681)
Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. (1994) (669)
Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. (1993) (611)
Multiple D2 dopamine receptors produced by alternative RNA splicing (1989) (602)
Regulation of transmembrane signaling by receptor phosphorylation (1987) (589)
Molecular cloning and expression of a 5-hydroxytryptamine7 serotonin receptor subtype. (1993) (505)
A targeted mutation of the D3 dopamine receptor gene is associated with hyperactivity in mice. (1996) (487)
Cross-talk between cellular signalling pathways suggested by phorbol-ester-induced adenylate cyclase phosphorylation (1987) (485)
Molecular cloning and expression of a D1 dopamine receptor linked to adenylyl cyclase activation. (1990) (465)
Interactions of the Novel Antipsychotic Aripiprazole (OPC-14597) with Dopamine and Serotonin Receptor Subtypes (1999) (395)
The classification of dopamine receptors: relationship to radioligand binding. (1983) (384)
Cloning, Characterization, and Chromosomal Localization of a Human 5‐HT6 Serotonin Receptor (1996) (366)
Receptor adaptations to centrally acting drugs. (1981) (299)
Anterior pituitary dopamine receptors. Demonstration of interconvertible high and low affinity states of the D-2 dopamine receptor. (1982) (272)
Molecular neurobiology of dopaminergic receptors. (1993) (256)
Molecular Cloning of a Novel G Protein‐Coupled Receptor Related to the Opiate Receptor Family (1995) (241)
Mechanism and Time Course of Cocaine-Induced Long-Term Potentiation in the Ventral Tegmental Area (2008) (235)
Cloning and expression of an A1 adenosine receptor from rat brain. (1991) (233)
New insights into dopaminergic receptor function using antisense and genetically altered animals. (1999) (231)
Expression of striatal D1 dopamine receptors coupled to inositol phosphate production and Ca2+ mobilization in Xenopus oocytes. (1990) (216)
Phorbol diesters promote beta-adrenergic receptor phosphorylation and adenylate cyclase desensitization in duck erythrocytes. (1984) (205)
Localization of serotonin subtype 6 receptor messenger RNA in the rat brain by in situ hybridization histochemistry (1995) (204)
Phosphorylation/dephosphorylation of the beta-adrenergic receptor regulates its functional coupling to adenylate cyclase and subcellular distribution. (1986) (203)
Cellular distribution of the rat D4 dopamine receptor protein in the CNS using anti-receptor antisera (1997) (202)
Role of the D1A dopamine receptor in the pathogenesis of genetic hypertension. (1996) (195)
Spatial learning deficit in dopamine D(1) receptor knockout mice. (1999) (192)
Disruption of dopamine D1 receptor gene expression attenuates alcohol-seeking behavior. (1998) (186)
Behavioral characterization of dopamine D5 receptor null mutant mice. (2001) (173)
Modulatory Actions of Dopamine on NMDA Receptor-Mediated Responses Are Reduced in D1A-Deficient Mutant Mice (1996) (169)
Mice Lacking D5 Dopamine Receptors Have Increased Sympathetic Tone and Are Hypertensive (2002) (156)
Protein Kinase C Mediates Phosphorylation, Desensitization, and Trafficking of the D2 Dopamine Receptor* (2004) (149)
The Concise Guide to Pharmacology 2013/14: Overview (2013) (143)
Dopamine receptor distribution in the rat CNS: elucidation using anti-peptide antisera directed against D1A and D3 subtypes (1994) (141)
Molecular characteristics of mammalian dopamine receptors. (1997) (139)
D1-like dopaminergic activation of phosphoinositide hydrolysis is independent of D1A dopamine receptors: evidence from D1A knockout mice. (1997) (134)
Medication discovery for addiction: translating the dopamine D3 receptor hypothesis. (2012) (133)
Phenotypic analysis of dopamine receptor knockout mice; recent insights into the functional specificity of dopamine receptor subtypes (2004) (132)
Functional Analysis of the Human D2 Dopamine Receptor Missense Variants* (1996) (129)
Dopaminergic inhibition of adenylate cyclase correlates with high affinity agonist binding to anterior pituitary D2 dopamine receptors (1984) (124)
Transfected D2 dopamine receptors mediate the potentiation of arachidonic acid release in Chinese hamster ovary cells. (1991) (120)
Desensitization of turkey erythrocyte adenylate cyclase. Beta-adrenergic receptor phosphorylation is correlated with attenuation of adenylate cyclase activity. (1984) (112)
The Role of Phosphorylation in D1 Dopamine Receptor Desensitization (2004) (109)
Dopamine D2 Receptor Overexpression Alters Behavior and Physiology in Drd2-EGFP Mice (2011) (106)
Homologous desensitization of adenylate cyclase is associated with phosphorylation of the beta-adrenergic receptor. (1985) (105)
A novel catecholamine-activated adenosine cyclic 3',5'-phosphate independent pathway for beta-adrenergic receptor phosphorylation in wild-type and mutant S49 lymphoma cells: mechanism of homologous desensitization of adenylate cyclase. (1986) (105)
Evidence against dopamine D1/D2 receptor heteromers (2014) (104)
Reconstitution of a hormone-sensitive adenylate cyclase system. The pure beta-adrenergic receptor and guanine nucleotide regulatory protein confer hormone responsiveness on the resolved catalytic unit. (1984) (102)
Dopamine 5 receptor mediates Ang II type 1 receptor degradation via a ubiquitin-proteasome pathway in mice and human cells. (2008) (101)
Phosphorylation of cell surface receptors: a mechanism for regulating signal transduction pathways. (1988) (99)
Striatal neurochemical changes in transgenic models of Huntington's disease (2002) (98)
D5 dopamine receptor regulation of reactive oxygen species production, NADPH oxidase, and blood pressure. (2006) (97)
The role of phosphorylation/dephosphorylation in agonist-induced desensitization of D1 dopamine receptor function: evidence for a novel pathway for receptor dephosphorylation. (2001) (96)
Interactions of novel dopaminergic ligands with D-1 and D-2 dopamine receptors. (1982) (95)
Characterization of Novel Fluorescent Ligands with High Affinity for D1 and D2 Dopaminergic Receptors (1989) (94)
Modification of cocaine self-administration by buspirone (buspar®): potential involvement of D3 and D4 dopamine receptors. (2013) (93)
High-potency ligands for DREADD imaging and activation in rodents and monkeys (2019) (92)
Dopamine receptor agonist potencies for inhibition of cell firing correlate with dopamine D3 receptor binding affinities. (1995) (91)
D5 Dopamine Receptors are Required for Dopaminergic Activation of Phospholipase C (2009) (90)
G Protein-coupled Receptor Kinase-mediated Phosphorylation Regulates Post-endocytic Trafficking of the D2 Dopamine Receptor* (2009) (90)
Interaction of Angiotensin II Type 1 and D5 Dopamine Receptors in Renal Proximal Tubule Cells (2005) (90)
Neurofilament-M Interacts with the D1 Dopamine Receptor to Regulate Cell Surface Expression and Desensitization (2002) (90)
D1 and D2 Dopamine Receptor Expression Is Regulated by Direct Interaction with the Chaperone Protein Calnexin* (2007) (89)
Localization of dopamine D1A receptor protein in rat kidneys. (1995) (89)
Interactions of ergot alkaloids with anterior pituitary D-2 dopamine receptors. (1983) (86)
Characterization of the 5′ flanking region of the human D1A dopamine receptor gene (1992) (85)
The D2S and D2L dopamine receptor isoforms are differentially regulated in Chinese hamster ovary cells. (1994) (83)
The D1 Dopamine Receptor Is Constitutively Phosphorylated by G Protein-Coupled Receptor Kinase 4 (2006) (82)
D1-D2 Dopamine Receptor Synergy Promotes Calcium Signaling via Multiple Mechanisms (2013) (80)
Pharmacological and behavioral divergence of ketamine enantiomers: implications for abuse liability (2021) (79)
Topographical evaluation of the phenotype of spontaneous behaviour in mice with targeted gene deletion of the D1A dopamine receptor: paradoxical elevation of grooming syntax (1998) (79)
D2 dopamine receptor internalization prolongs the decrease of radioligand binding after amphetamine: A PET study in a receptor internalization-deficient mouse model (2010) (77)
Zinc Allosterically Modulates Antagonist Binding to Cloned D1 and D2 Dopamine Receptors (1997) (76)
[3H]7-OH-DPAT is capable of labeling dopamine D2 as well as D3 receptors. (1995) (76)
Regulation of ligand binding to pituitary D-2 dopaminergic receptors. Effects of divalent cations and functional group modification. (1983) (75)
Regulation of D(1) dopamine receptors with mutations of protein kinase phosphorylation sites: attenuation of the rate of agonist-induced desensitization. (1999) (75)
Localization of D2 dopamine receptors in vertebrate retinae with anti‐peptide antibodies (1993) (73)
N-(3-fluoro-4-(4-(2-methoxy or 2,3-dichlorophenyl)piperazine-1-yl)butyl)arylcarboxamides as selective dopamine D3 receptor ligands: critical role of the carboxamide linker for D3 receptor selectivity. (2011) (69)
Discovery and Characterization of a G Protein–Biased Agonist That Inhibits β-Arrestin Recruitment to the D2 Dopamine Receptor (2014) (69)
Desensitization of the turkey erythrocyte beta-adrenergic receptor in a cell-free system. Evidence that multiple protein kinases can phosphorylate and desensitize the receptor. (1985) (69)
G Protein-coupled Receptor Kinase-2 Constitutively Regulates D2 Dopamine Receptor Expression and Signaling Independently of Receptor Phosphorylation* (2009) (69)
Phorbol diester treatment promotes enhanced adenylate cyclase activity in frog erythrocytes. (1986) (68)
Dopamine receptor binding on intact cells. Absence of a high-affinity agonist-receptor binding state. (1983) (66)
Conservation of behavioural topography to dopamine D1-like receptor agonists in mutant mice lacking the D1A receptor implicates a D1-like receptor not coupled to adenylyl cyclase (1999) (66)
Dopaminergic Signaling in the Cochlea: Receptor Expression Patterns and Deletion Phenotypes (2012) (66)
D2 dopamine receptor localization on striatonigral neurons (1992) (64)
Cellular distribution of the rat D1B receptor in central nervous system using anti-receptor antisera (1997) (64)
D2 dopamine receptor distribution in the rodent CNS using anti-peptide antisera (1993) (64)
Characterization of anti-peptide antibodies for the localization of D2 dopamine receptors in rat striatum. (1991) (63)
Analysis of neuroleptic binding affinities and potencies for the different human D2 dopamine receptor missense variants. (1999) (62)
Agonist-induced desensitization of D2 dopamine receptors in human Y-79 retinoblastoma cells. (1991) (62)
Comparison of dopamine D1 and D5 receptor knockout mice for cocaine locomotor sensitization (2008) (61)
Imaging the high-affinity state of the dopamine D2 receptor in vivo: fact or fiction? (2012) (60)
Coexpression of striatal dopamine receptor subtypes and excitatory amino acid subunits (1997) (60)
Assignment of the 5HT7 receptor gene (HTR7) to chromosome 10q and exclusion of genetic linkage with Tourette syndrome. (1995) (60)
Clozapine: Selective Labeling of Sites Resembling 5HT6 Serotonin Receptors May Reflect Psychoactive Profile (1995) (59)
Zinc modulates antagonist interactions with D2-like dopamine receptors through distinct molecular mechanisms. (1999) (58)
Dopamine receptors in the central nervous system. (1982) (58)
D4 dopamine receptor binding affinity does not distinguish between typical and atypical antipsychotic drugs (1995) (58)
Agonist-induced desensitization of D1-dopamine receptors linked to adenylyl cyclase activity in cultured NS20Y neuroblastoma cells. (1990) (57)
Ascorbic acid enables reversible dopamine receptor 3H-agonist binding. (1981) (54)
Direct visualization and cellular localization of D1 and D2 dopamine receptors in rat forebrain by use of fluorescent ligands. (1989) (54)
Organ specificity of the dopamine1 receptor/adenylyl cyclase coupling defect in spontaneously hypertensive rats. (1993) (53)
The binding-site crevice of the D4 dopamine receptor is coupled to three distinct sites of allosteric modulation. (2001) (52)
Expression of dopamine D1A receptor gene in proximal tubule of rat kidneys. (1993) (52)
Chronic estrogen treatment promotes a functional uncoupling of the D2 dopamine receptor in rat anterior pituitary gland. (1989) (51)
Locomotor and discriminative-stimulus effects of cocaine in dopamine D5 receptor knockout mice (2003) (51)
D2L, D2S, and D3 dopamine receptors stably transfected into NG108‐15 cells couple to a voltage‐dependent potassium current via distinct G protein mechanisms (1996) (50)
Regulation of D1A and D2 dopamine receptor mRNA during ontogenesis, lesion and chronic antagonist treatment. (1992) (49)
Nervous system disorders (2006) (49)
Reciprocal Modulation of Function between the D1 and D2 Dopamine Receptors and the Na+,K+-ATPase* (2008) (48)
Reduction in Acetylcholine Release in the Hippocampus of Dopamine D5 Receptor-Deficient Mice (2004) (48)
Association of sequestered beta-adrenergic receptors with the plasma membrane: a novel mechanism for receptor down regulation. (1984) (48)
Electrophysiological and Morphological Analyses of Cortical Neurons Obtained from Children with Catastrophic Epilepsy: Dopamine Receptor Modulation of Glutamatergic Responses (1999) (47)
Dopamine receptor binding in bovine intermediate lobe pituitary membranes. (1980) (46)
New roles for dopamine D2 and D3 receptors in pancreatic beta cell insulin secretion (2018) (46)
D2 dopamine receptor protein location: Golgi impregnation‐gold toned and ultrastructural analysis of the rat neostriatum (1994) (45)
Identification of G protein-biased agonists that fail to recruit β-arrestin or promote internalization of the D1 dopamine receptor. (2015) (45)
Agonist interactions with dopamine receptors: focus on radioligand-binding studies. (1984) (42)
Multiple fluorescent ligands for dopamine receptors. II. Visualization in neural tissues (1991) (40)
Dopamine D1 vs D5 receptor-dependent induction of seizures in relation to DARPP-32, ERK1/2 and GluR1-AMPA signalling (2008) (40)
Pharmacological characterization of 2‐methoxy‐N‐propylnorapomorphine's interactions with D2 and D3 dopamine receptors (2009) (40)
Dopamine D5 receptor modulates male and female sexual behavior in mice (2005) (39)
Regulation of Dopamine Receptor Function and Expression (1997) (39)
Ethological resolution of behavioural topography and D1‐like versus D2‐like agonist responses in congenic D5 dopamine receptor mutants: Identification of D5:D2‐like interactions (2005) (39)
Lack of renal dopamine D5 receptors promotes hypertension. (2011) (39)
The elevated blood pressure of human GRK4gamma A142V transgenic mice is not associated with increased ROS production. (2007) (38)
Advances and challenges in the search for D2 and D3 dopamine receptor-selective compounds. (2018) (38)
Synthesis and Pharmacological Characterization of Novel trans-Cyclopropylmethyl-Linked Bivalent Ligands That Exhibit Selectivity and Allosteric Pharmacology at the Dopamine D3 Receptor (D3R). (2017) (38)
D5 dopamine receptor regulation of phospholipase D. (2005) (37)
Upregulation of Renal Sodium Transporters in D5 Dopamine Receptor–Deficient Mice (2010) (37)
Handbook of contemporary neuropharmacology (2007) (35)
Dopamine receptors: subtypes, localization and regulation. (1981) (34)
Expression of rat striatal D1 and D2 dopamine receptor mRNAs: Ontogenetic and pharmacological studies (1992) (34)
Multiple fluorescent ligands for dopamine receptors. I. Pharmacological characterization and receptor selectivity (1991) (34)
Molecular Pharmacology of the Dopamine Receptors (2009) (34)
Arrestin3 mediates D2 dopamine receptor internalization (2009) (33)
Agonist‐induced morphologic decrease in cellular d1A dopamine receptor staining (1997) (33)
Nonconserved residues in the second transmembrane-spanning domain of the D(4) dopamine receptor are molecular determinants of D(4)-selective pharmacology. (2000) (32)
D2 dopamine receptor expression and trafficking is regulated through direct interactions with ZIP (2008) (32)
Classification of dopamine receptors. (1983) (32)
CNS Dopamine Receptors (1983) (31)
Occupancy of dopamine D2/3 receptors in rat brain by endogenous dopamine measured with the agonist positron emission tomography radioligand [11C]MNPA (2008) (31)
D2S, D2L, D3, and D4 dopamine receptors couple to a voltage‐dependent potassium current in N18TG2 × mesencephalon hybrid cell (MES‐23.5) via distinct G proteins (1999) (30)
Identification of RanBP 9/10 as Interacting Partners for Protein Kinase C (PKC) γ/δ and the D1 Dopamine Receptor: Regulation of PKC-Mediated Receptor Phosphorylation (2010) (30)
Ethanol Regulation of D1 Dopamine Receptor Signaling is Mediated by Protein Kinase C in an Isozyme-Specific Manner (2008) (30)
Beta-adrenergic receptor-coupled adenylate cyclase. Biochemical mechanisms of regulation. (1987) (30)
Radioligand binding studies: evidence for multiple dopamine receptors. (1979) (29)
Dephosphorylation of the beta 2-adrenergic receptor and rhodopsin by latent phosphatase 2. (1988) (29)
Novel Analogues of (R)-5-(Methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinolin-2(1H)-one (Sumanirole) Provide Clues to Dopamine D2/D3 Receptor Agonist Selectivity (2016) (29)
Identification and characterization of D1 and D2 dopamine receptors in cultured neuroblastoma and retinoblastoma clonal cell lines (1989) (28)
D5 Dopamine Receptor Knockout Mice and Hypertension (2004) (28)
Guanine nucleotides regulate anterior pituitary dopamine receptors. (1979) (28)
Dopamine regulates pancreatic glucagon and insulin secretion via adrenergic and dopaminergic receptors (2021) (28)
Identification of Positive Allosteric Modulators of the D1 Dopamine Receptor That Act at Diverse Binding Sites (2018) (28)
Structural basis for Na(+)-sensitivity in dopamine D2 and D3 receptors. (2015) (28)
Transfected D2 short dopamine receptors inhibit voltage-dependent potassium current in neuroblastoma x glioma hybrid (NG108-15) cells. (1993) (27)
Where Structure Meets Function (1998) (27)
Behavioral characterization of dopamine D-sub-5 receptor null mutant mice. (2001) (27)
Cloning of a 'D3' receptor subtype expands dopamine receptor family. (1991) (26)
(-)-Stepholidine is a potent pan-dopamine receptor antagonist of both G protein- and β-arrestin-mediated signaling (2015) (24)
G Protein-coupled Receptor Kinase-mediated Phosphorylation Regulates Post-endocytic Trafficking of the D 2 Dopamine Receptor * (2009) (24)
Dopamine β‐hydroxylase‐deficient mice have normal densities of D2 dopamine receptors in the high‐affinity state based on in vivo PET imaging and in vitro radioligand binding (2010) (24)
Investigation of the binding and functional properties of extended length D3 dopamine receptor-selective antagonists (2015) (24)
Phosphorylation of the beta-adrenergic receptor in intact cells: relationship to heterologous and homologous mechanisms of adenylate cyclase desensitization. (1987) (23)
Discovery, Optimization, and Characterization of Novel D2 Dopamine Receptor Selective Antagonists (2014) (22)
The E2.65A mutation disrupts dynamic binding poses of SB269652 at the dopamine D2 and D3 receptors (2018) (22)
Synthesis and processing of D2 dopamine receptors. (1993) (22)
Cell-free desensitization of catecholamine-sensitive adenylate cyclase. Agonist- and cAMP-promoted alterations in turkey erythrocyte beta-adrenergic receptors. (1984) (21)
Molecular neurobiology of dopamine receptor subtypes (1992) (21)
Pseudo non-competitive agonist interactions with dopamine receptors. (1980) (20)
Cyclic AMP-Mediated Desensitization of D1 Dopamine Receptor-Coupled Adenylyl Cyclase in NS20Y Neuroblastoma Cells (1994) (20)
A structural basis for how ligand binding site changes can allosterically regulate GPCR signaling and engender functional selectivity (2020) (20)
Regulation of Heterogeneity in D2 Dopamine Receptor Gene Expression among Individual Melanotropes in the Rat Pituitary Intermediate Lobe (1994) (20)
Altered regulation of the D(1) dopamine receptor in mutant Chinese hamster ovary cells deficient in cyclic AMP-dependent protein kinase activity. (2000) (20)
Chimeric D2/D3 dopamine receptor coupling to adenylyl cyclase. (1997) (19)
Dopamine D1 and D5 receptors differentially regulate oxidative stress through paraoxonase 2 in kidney cells (2015) (18)
Dopamine D4 Receptor-Selective Compounds Reveal Structure–Activity Relationships that Engender Agonist Efficacy (2019) (18)
D 1-like Dopaminergic Activation of Phosphoinositide Hydrolysis Is Independent of D 1 A Dopamine Receptors : Evidence from D 1 A Knockout Mice (1997) (17)
Protein Kinase C Mediates Phosphorylation , Desensitization and Trafficking of the D 2 Dopamine Receptor (2004) (17)
Expression of Functional D2 Dopamine Receptors Following Differentiation of Y‐79 Human Retinoblastoma Cells (1990) (16)
Photoaffinity labeling of turkey erythrocyte beta-adrenergic receptors: degradation of the Mr = 49,000 protein explains apparent heterogeneity. (1984) (16)
Dopamine Reduction of GABA Currents in Striatal Medium-sized Spiny Neurons is Mediated Principally by the D1 Receptor Subtype (2007) (16)
The Dopamine D5 receptor contributes to activation of cholinergic interneurons during L-DOPA induced dyskinesia (2020) (14)
Striatal Excitatory Amino Acid Receptor Subunit Expression in the D1A-Dopamine Receptor-Deficient Mouse (1998) (14)
A Mechanism Linking Two Known Vulnerability Factors for Alcohol Abuse: Heightened Alcohol Stimulation and Low Striatal Dopamine D2 Receptors (2019) (14)
Disruption of orofacial movement topographies in congenic mutants with dopamine D5 but not D4 receptor or DARPP-32 transduction ‘knockout’ (2006) (14)
Melanotrope dopamine D2 receptor isoform expression in the developing rat pituitary (1996) (14)
Photoaffinity labeling of β-adrenergic receptors in mammalian tissues (1984) (14)
D1 Dopamine Receptor (2008) (14)
D2 Dopamine Receptor (2008) (14)
Sensitization of frog erythrocyte adenylate cyclase system by tumor-promoting phorbol diesters. (1985) (13)
N-(p-isothiocyanatophenethyl)spiperone, a selective and irreversible antagonist of D2 dopamine receptors in brain. (1991) (13)
Activation of the dopamine 1 and dopamine 5 receptors increase skeletal muscle mass and force production under non-atrophying and atrophying conditions (2011) (12)
The Dopamine D5 Receptor Is Involved in Working Memory (2017) (12)
Regulation of the D1 dopamine receptor through cAMP-mediated pathways. (1998) (12)
Discovery, Optimization and Characterization of ML417: A Novel and Highly Selective D3 Dopamine Receptor Agonist. (2020) (12)
Dopamine Receptor-Interacting Proteins (2010) (12)
Structure-Activity Investigation of a G Protein-Biased Agonist Reveals Molecular Determinants for Biased Signaling of the D2 Dopamine Receptor (2018) (12)
Evidence for a stereoselective mechanism for bitopic activity by extended-length antagonists of the D3 dopamine receptor. (2020) (12)
Kinetic brain analysis and whole-body imaging in monkey of [11C]MNPA, a dopamine agonist radioligand (2008) (11)
Target deconvolution studies of (2R,6R)-hydroxynorketamine: an elusive search (2022) (11)
Radioligand Binding Studies of Agonist Interactions with Dopamine Receptors (1984) (11)
Comments on the commentary by Dr. Seeman (1982) (10)
PNA-Based Multivalent Scaffolds Activate the Dopamine D2 Receptor. (2015) (10)
Pharmacological Characterization of Mammalian D1 and D2 Dopamine Receptors Expressed in Drosophila Schneider‐2 Cells (2003) (10)
Dopamine receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database (2019) (9)
D1-Like Dopamine Receptor-Mediated Function in Congenic Mutants with D1 vs. D5 Receptor “Knockout” (2004) (9)
Enhanced adenylate cyclase activity of turkey erythrocytes following treatment with beta-adrenergic receptor antagonists. (1984) (8)
Behavioral analysis of multiple D1-like dopamine receptor subtypes: new agents and studies in transgenic mice with D1A receptor knockout. (1998) (8)
β-Adrenergic receptor-coupled adenylate cyclase (2008) (8)
Dopamine receptors in the central nervous system. (1983) (8)
Molecular Neuroscience (2011) (7)
Dopamine-receptor subtype-selective agonists in the treatment of Parkinson's disease (1995) (7)
Susceptibility of dopamine D5 receptor targeted mice to cysteamine (2001) (7)
Dopamine D5 receptor-mediated decreases in mitochondrial reactive oxygen species production are cAMP and autophagy dependent (2021) (6)
Dopamine D₁-like receptors regulate the α₁A-adrenergic receptor in human renal proximal tubule cells and D₁-like dopamine receptor knockout mice. (2014) (6)
The E 2 . 65 A mutation disrupts dynamic binding poses of SB 269652 at the dopamine D 2 and D 3 receptors (2018) (6)
Dopamine D 1 vs D 5 receptor-dependent induction of seizures in relation to DARPP-32 , ERK 1 / 2 and GluR 1-AMPA signalling (2015) (6)
Solubilization of phencyclidine receptors from rat cerebral cortex in an active ligand binding state. (1989) (6)
Pharmacological Characterization of the Imipridone Anticancer Drug ONC201 Reveals a Negative Allosteric Mechanism of Action at the D2 Dopamine Receptor (2021) (6)
Ligand with Two Modes of Interaction with the Dopamine D2 Receptor–An Induced-Fit Mechanism of Insurmountable Antagonism (2020) (6)
Modiﬁcation of cocaine self-administration by buspirone (buspar 1 ): potential involvement of D 3 and D 4 dopamine receptors (2012) (6)
Molecular mechanisms of beta-adrenergic receptor desensitization. (1987) (6)
Plasticity and Ontogeny of Melanotrope D2A Dopamine Receptor mRNA and Isoform Protein Expression (1993) (5)
Disruption of dopamine D receptor gene expression attenuates (1998) (5)
Atypical neuroleptics have low affinity for dopamine D2 receptors or are selective for D4 receptors: Commentary [2] (1997) (5)
Cardiovascular-Kidney Interactions in Health and Disease D 5 dopamine receptor regulation of reactive oxygen species production , NADPH oxidase , and blood pressure (2005) (5)
Multiple daily amphetamine administration decreases both [3H]agoinst and [3]antagonist dopamine receptor binding (1982) (4)
D3 Dopamine Receptor (2007) (4)
D2-like Dopamine Receptors (2008) (4)
Development of Pyrimidone D1 Dopamine Receptor Positive Allosteric Modulators. (2020) (4)
A new era of rationally designed antipsychotics (2018) (4)
Cardiovascular-Renal Mechanisms in Health and Disease The elevated blood pressure of human GRK 4 A 142 V transgenic mice is not associated with increased ROS production (2007) (4)
Chemogenetic ligands for translational neurotheranostics (2018) (4)
Abstract 3877: IND-enabling characterization of DRD2/3 imipridone antagonist ONC206 for oncology (2019) (4)
D5 dopamine receptor regulation of reactive oxygen species production and blood pressure in mice (2004) (4)
Tandem sulfur-containing amino acids are epicritical determinants of dopamine D(2) receptor pharmacology. (2000) (3)
Non-N-Methyl D-Aspartate Receptors Are Involved in the Hypertension of D5 Dopamine Receptor Knockout Mice. (2000) (3)
Radioligand Binding Studies of Dopamine Receptors in the Central Nervous System (1983) (3)
Novel Cryo-EM structures of the D1 dopamine receptor unlock its therapeutic potential (2021) (3)
Direct demonstration of D1 dopamine receptors in the bovine parathyroid gland using the D1 selective antagonist [125I]‐SCH 23982 (1989) (3)
D5 Dopamine Receptor (2008) (3)
Adenylate cyclase coupled beta-adrenergic receptors: biochemical mechanisms of desensitization. (1986) (2)
P-396: D5 dopamine regulation of phospholipase D and blood pressure in mice (2002) (2)
Discovery, optimization, and characterization of a novel series of dopamine D2 versus D3 receptor selective antagonists (2013) (2)
Membrane lipid rafts are required for D2 dopamine receptor signaling (2011) (2)
Cell-free Desensitization of Catecholamine-sensitive Adenylate (1984) (2)
A new era of rationally designed antipsychotics. (2018) (2)
[21] Development of antireceptor antibodies using synthetic peptides (1995) (2)
P.2.27 Topographical evaluation of spontaneous and agonist-induced behaviour in mutants with congenic dopamine D4 versus D5 receptor knockout (2004) (2)
Cell‐free Desensitization of the β‐Adrenergic Receptor: Evidence that Multiple Protein Kinases Can Phosphorylate and Desensitize the Receptor (1986) (1)
D1-like Dopamine Receptors (2008) (1)
DDRE-33. MOLECULAR DIFFERENTIATION OF IMIPRIDONES ONC201 AND ONC206 (2020) (1)
Characterization of a D1 Dopamine Receptor Positive Allosteric Modulator with a Novel Binding Site (2021) (1)
Biology of Free Radicals D 5 dopamine receptor regulation of phospholipase D (2004) (1)
Homologous desensitization of adenylate cyclase: the role of. beta. -adrenergic receptor phosphorylation and dephosphorylation (1986) (1)
Dopamine D 1 -like receptors regulate the (cid:2) 1A -adrenergic receptor in human renal proximal tubule cells and D 1 -like dopamine receptor knockout mice (2014) (1)
DDIS-20. IMIPRIDONE STRUCTURE ACTIVITY RELATIONSHIP UNCOVERS ONC206 AS THE NEXT BITOPIC DRD2 ANTAGONIST FOR ONCOLOGY WITH DIFFERENTIATED RECEPTOR PHARMACOLOGY (2019) (1)
EXTH-33. RECEPTOR PHARMACOLOGY OF ONC201: THE FIRST BITOPIC DRD2 ANTAGONIST FOR CLINICAL NEURO-ONCOLOGY (2019) (1)
Discovery and Characterization of a G Protein – Biased Agonist That Inhibits b-Arrestin Recruitment to the D 2 Dopamine Receptor s (2014) (1)
Pharmacological characterization of the interactions of 2-methoxy-N-propylnorapomorphine (MNPA) with D2 and D3 dopamine receptors (2008) (1)
Structurally Diverse Positive Allosteric Modulators of the D1 Dopamine Receptor Potentiate G‐Protein and β‐Arrestin‐Mediated Signaling (2016) (1)
G Protein-coupled Receptor Kinase-mediated Phosphorylation Regulates Post-endocytic Trafficking of (2009) (1)
Regulation of cellular signal transduction pathways by densensitization and amplification (1994) (1)
Irwin J Kopin (2017) (1)
Comprar Handbook of Contemporary Neuropharmacology, 3 Volume Set | Phil Skolnick | 9780471660538 | Wiley (2007) (1)
Delineation of G Protein-Coupled Receptor Kinase Phosphorylation Sites within the D1 Dopamine Receptor and Their Roles in Modulating β-Arrestin Binding and Activation (2023) (0)
microgravitymouse as a model of cardiovascular adaptations to (2015) (0)
Preface (2012) (0)
Preface (2005) (0)
Structure‐Activity Relationships of a Negative Allosteric Modulator of the D3 Dopamine Receptor and Investigation of its Binding Site (2020) (0)
Table 1, Screen Quest™ Fluor-8 of D2 Ca2+ qHTS assay protocol (2013) (0)
The show must go on. Reply to “Distinct functions of S-ketamine and R-ketamine in mediating biobehavioral processes of drug dependency: comments on Bonaventura et al” by Insop Shim (2022) (0)
EXTH-43. DIFFERENTIATED PHARMACOLOGY OF THE IMIPRIDONE ONC201, THE FIRST SELECTIVE DRD2/3 ANTAGONIST IN CLINICAL NEURO-ONCOLOGY (2017) (0)
Gene Cloning, Expression, and Mutagenesis (2011) (0)
Table 4, Detailed protocol for the DiscoveRx D3 PathHunter® β-arrestin selectivity assay (2013) (0)
Figure 2, Structures of the ML321 and five analogs (with corresponding SID) that have been submitted to the MLSMR compound repository (2013) (0)
Abstract 3857: Selective targeting of dopamine receptor dysregulation in high grade gliomas with imipridone ONC201 (2018) (0)
Synaptic Transmission: Intracellular Signaling (2007) (0)
2004 CARDIOVASCULAR AND KIDNEY INVESTIGATORS MEETING Biology of Free Radicals D5 dopamine receptor regulation of phospholipase D (2005) (0)
Optimization of a novel D2 dopamine receptor antagonist with unprecedented selectivity as a therapeutic to treat psychosis and other neuropsychiatric disorders (2020) (0)
l‐Stepholidine is a potent pan‐dopamine receptor antagonist at G protein and β‐arrestin mediated signaling in vitro (662.5) (2014) (0)
MechanismandTimeCourseofCocaine-InducedLong- TermPotentiationintheVentralTegmentalArea (2008) (0)
50. New Roles for Peripheral Dopamine D2-Like Receptors in Antipsychotic Drug-Induced Metabolic Dysfunction (2019) (0)
Phosphorylation / dephosphorylation of the jB-adrenergic receptor regulates its functional coupling to adenylate cyclase and subcellular distribution ( homologous desensitization / hormone receptor / receptor sequestration / protein phosphatase ) (0)
Abstract B130: Differentiated pharmacology of the imipridone ONC201: the first selective DRD2/3 antagonist in clinical oncology (2018) (0)
1472-P: Dual Pancreatic Adrenergic and Dopaminergic Signaling as a Therapeutic Mechanism for Treatment of Dysglycemia by Bromocriptine (2022) (0)
Table 5, Detailed protocol for the D3 binding selectivity assay (2013) (0)
Identification of a novel, highly potent D3 dopamine receptor‐selective agonist (662.8) (2014) (0)
Development of a dopaminergic neurodegeneration assay using laser cytometry of Caenorhabditis elegans models of Parkinson’s disease (2020) (0)
Identification of Structural Elements that Regulate Signaling Bias in D2-like Dopamine Receptors (2018) (0)
Publisher Correction: The Dopamine D5 receptor contributes to activation of cholinergic interneurons during L-DOPA induced dyskinesia (2020) (0)
Binding of atypical antipsychotic drugs to novel neurotransmitter receptors (1996) (0)
Characterization of D1 and D2 dopamine receptor interactions with the Na+/K+‐ATPase (2006) (0)
Molecular Neuroscience (2005) (0)
Discovery and characterization of a G protein‐biased agonist of the D2 dopamine receptor (662.7) (2014) (0)
Evidence for a Novel Mechanism of Regulation (2005) (0)
Abstract 1752: Cross-transplantation Studies Demonstrate the Role of Renal Dopamine D5 Receptors in Hypertension (2008) (0)
Dopamine Receptors.Ian Creese , Claire M. Fraser (1988) (0)
Table 9, Summary of in vivo pharmacokinetic (PK) data for ML321 in C57BL/6 mice (BQL = Below quantifiable limit of 1 ng/mL for ML321 in male C57BL/6 plasma. NA = Not available) (2013) (0)
Table 3, Detailed protocol for the D2 binding secondary assay (2013) (0)
Abstract 5688: IND-enabling characterization of ONC206 as the next bitopic antagonist for oncology (2020) (0)
Investigation of the D1-D2 heteromer: Pharmacology, subunit composition, and mechanisms of signaling (2013) (0)
Molecular cloning andexpression ofaD1dopamine receptor linked toadenylyl cyclase activation (1990) (0)
P-439: Hypertension and PLD2 regulation by D5 dopamine receptor (2005) (0)
EXTH-17. SELECTIVE, NON-COMPETITIVE DRD2/3 ANTAGONISM BY IMIPRIDONE ONC206 IS EFFECTIVE IN TUMORS WITH DOPAMINE RECEPTOR DYSREGULATION (2018) (0)
Molecular Neuroscience (2006) (0)
Dopamine D1 and D5 receptors: molecular cloning and pharmacological characteristics (1994) (0)
Photoaffinity labeling of beta-adrenergic receptors in mammalian tissues. (1984) (0)
Molecular Neuroscience (2007) (0)
C12 Cloning of an adenosine A, receptor from rat brain: Characterization and expression in vitro and in the developing CNS (1992) (0)
High‐throughput screening for novel allosteric modulators of the D1 dopamine receptor (662.4) (2014) (0)
High-Throughput Screening for Modulators of the D 2 Dopamine Receptor Yields Unique and Selective Pharmacological Chemotypes (2013) (0)
Table 10, Comparison of dopamine receptor inhibition assay for ML321 and current D2 antagonists (2013) (0)
Abstracts from the ASENT 18th Annual Meeting (2016) (0)
Table 6, List of the D2 DAR inhibitor probe ML321 and related analogs and their corresponding identification numbers (2013) (0)
Occupancy of dopamine D2/D3 receptors in rat brain by endogenous dopamine measured with the agonist positron emission tomography radioligand [11C]MNPA (2008) (0)
The G-protein linked receptor facts book: Steve Watson and Steve Arkinstall, Academic Press, 1994. £19.50 (xi + 427 pages) ISBN 012 738440 5 (1994) (0)
Scheme 1, The synthetic route to ML321 is a multi-step process with 8 compound intermediates (A – H) (2013) (0)
Identification of allosteric modulators of the D2 dopamine receptor (662.6) (2014) (0)
Table 2, Detailed protocol of DiscoveRx D2 β-arrestin secondary assay (2013) (0)
Characterization of anti-peptide antibodies for the localization of D 2 dopamine receptors in rat striatum ( caudate nudeus / cholinergic interneuron / projection neuron ) (2004) (0)
Molecular Neuroscience (2002) (0)
Publisher Correction: The Dopamine D5 receptor contributes to activation of cholinergic interneurons during L-DOPA induced dyskinesia (2020) (0)
Optimization of ML321: a D2 dopamine receptor‐selective antagonist for the treatment of neuropsychiatric disorders (2021) (0)
Short Communication Arrestin3 Mediates D 2 Dopamine Receptor Internalization (2009) (0)
Table 11, GPCR panel screening for ML321 and compound 58 (2013) (0)
Table 8, In vitro ADME profile for probe ML321 and a relative analog NCGC00109414 (CID16007814) (2013) (0)
CENTRALLY ACTING DRUGS (1981) (0)
Phosphorylation of the D1 Dopamine Receptor by G Protein‐Coupled Receptor Kinases: phosphorylation site identification and linkage to functional effects (2021) (0)
DDIS-12. ONC201: THE FIRST SELECTIVE, NON-COMPETITIVE DRD2/3 ANTAGONIST FOR CLINICAL NEURO-ONCOLOGY (2018) (0)
Direct radioligand measurement of dopamine receptors in the anterior pituitary gland. (1983) (0)
High‐throughput screening for identification of novel allosteric modulators of the D3 dopamine receptor (2015) (0)
Structural Insights Into D1 Dopamine Receptor Phosphorylation and Desensitization (2002) (0)
The Dopamine D5 receptor contributes to activation of cholinergic interneurons during L-DOPA induced dyskinesia (2020) (0)
Figure 4, Known chemical series of selective D2versus D3 DAR antagonist (2013) (0)
DopaminergicSignalingintheCochlea:ReceptorExpression PatternsandDeletionPhenotypes (2012) (0)
Calcium and Phospholipase Cβ Signaling Through Dopamine Receptors (2015) (0)
Identification of a novel dopaminergic agonist that displays locational bias and functional selectively at the D2 dopamine receptor (2015) (0)
Preface (1997) (0)
Gene Cloning, Expression, and Mutagenesis (2002) (0)
National scientific medical meeting 1997 abstracts (1998) (0)
Identification of a novel negative allosteric modulator of the D3 dopamine receptor (2016) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With David Robert Sibley?

David Robert Sibley is affiliated with the following schools:

David Robert Sibley's Academic­Influence.com Rankings